Real-World evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
CONCLUSIONS: In CANA-treated patients and patient subgroups from a network of Florida hospitals, improvements in quality measures and response durability were similar to clinical trials and other real-world studies.
PMID: 29468896 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canagliflozin | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Electronic Medical Records (EMR) | Endocrinology | Invokana | Primary Care | Research | Study | Weight Loss